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Abstract 
Background: The lack of translatable in vitro blood‑tumor barrier (BTB) models creates challenges in the develop‑
ment of drugs to treat tumors of the CNS and our understanding of how the vascular changes at the BBB in the pres‑
ence of a tumor.
Methods: In this study, we characterize a novel microfluidic model of the BTB (and BBB model as a reference) that 
incorporates flow and induces shear stress on endothelial cells. Cell lines utilized include human umbilical vein 
endothelial cells co‑cultured with CTX‑TNA2 rat astrocytes (BBB) or Met‑1 metastatic murine breast cancer cells (BTB). 
Cells were capable of communicating across microfluidic compartments via a porous interface. We characterized the 
device by comparing permeability of three passive permeability markers and one marker subject to efflux.
Results: The permeability of Sulforhodamine 101 was significantly (p < 0.05) higher in the BTB model 
(13.1 ± 1.3 × 10−3, n = 4) than the BBB model (2.5 ± 0.3 × 10−3, n = 6). Similar permeability increases were observed 
in the BTB model for molecules ranging from 600 Da to 60 kDa. The function of P‑gp was intact in both models and 
consistent with recent published in vivo data. Specifically, the rate of permeability of Rhodamine 123 across the BBB 
model (0.6 ± 0.1 × 10−3, n = 4), increased 14‑fold in the presence of the P‑gp inhibitor verapamil (14.7 ± 7.5 × 10−3, 
n = 3) and eightfold with the addition of Cyclosporine A (8.8 ± 1.8 × 10−3, n = 3). Similar values were noted in the 
BTB model.
Conclusions: The dynamic microfluidic in vitro BTB model is a novel commercially available model that incorporates 
shear stress, and has permeability and efflux properties that are similar to in vivo data.
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Background
The occurrence of brain metastases in breast cancer 
patients is approximately 10–16% [1]. Due to improve-
ments in chemotherapy, the overall survival of breast 
cancer patients has increased. Unfortunately with pro-
longed survival the incidence of patients developing 
symptomatic brain metastases has also increased. One of 
the leading complications of brain metastases is the ina-
bility of drugs to reach the tumor at concentrations ade-
quate to induce cytotoxicity. This is due, in part, to the 
presence of a partially intact blood–brain barrier (BBB).
The BBB is a complex anatomical network, functioning 
to strictly regulate the movement of molecules and ions 
from the blood to the brain and back. In addition, the BBB 
serves as the conduit to supply the brain with the essential 
nutrients it needs, while facilitating the excretion of waste 
products through efflux [2]. The hallmark of the BBB is 
the presence of endothelial cells that are tightly connected 
by tight junction protein complexes, which are composed 
of claudins, occludins, and junction adhesion molecules 
[3]. In addition to endothelia, the BBB has a thick basal 
membrane with pericytes and astrocytic foot processes 
in close proximity [4, 5]. The net effect of this anatomical 
structure results in the transendothelial electrical resist-
ance (TEER) of brain capillaries being  ~2000  O*cm2, in 
comparison to 2–20  O*cm2 in peripheral capillaries [6, 
7]. In addition to the structural components, the BBB is 
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highly enriched in efflux transporters that actively restrict 
the entry a large and diverse set of lipophilic solutes from 
accumulating in the brain [8, 9].
When metastatic cancer cells invade the CNS, they 
may eventually colonize and proliferate into a larger 
tumor mass. Once the lesion has grown to a point that it 
has areas of hypoxia, the tumor will secrete high amounts 
of vascular endothelial growth factor in an attempt to 
develop a new blood supply [10, 11]. This vasculature 
(blood-tumor barrier; BTB) is different than the BBB 
predominantly because astrocytes, pericytes, and neu-
rons are no longer in close proximity to the capillary. It is 
hypothesized that these anatomical changes result in vas-
culature that has greater permeability than the BBB [12]. 
The BTB may also have a somewhat different and varied 
expression of efflux transporters depending on the CNS 
malignancy [13–15]. Despite the apparent breakdown 
of the BBB in the presence of a tumor [16], the BTB still 
limits drug movement into the CNS lesion significantly 
more than in peripheral tumors.
Currently, there are no widely validated in vitro mod-
els of the BTB. The most widely used in vitro BBB model, 
which also has been used to model the BTB, is a transwell 
insert system. Briefly, the model consists of an upper 
chamber with endothelial cells grown on the surface sep-
arated from a lower chamber that may or may not con-
tain astrocytes and or cancer cells. The two chambers are 
separated by a porous membrane [17, 18]. Drug move-
ment is modeled by measuring accumulation in the lower 
chamber versus time.
However, the transwell model has limitations. First, there 
is a lack of flow exerted on the endothelia resulting in poor 
cell morphology and a “leakier” barrier compared to in vivo 
data [17–21]. Second, endothelial cells do not uniformly 
attach to the outer walls of the insert, leaving gaps between 
endothelial cells and the edge of the insert, also resulting in 
increased permeability [22]. Third, an unstirred water later 
forms on the surface of the endothelia, which results in 
increased permeability for hydrophilic drugs and decreased 
permeability for lipid soluble drugs [23, 24].
Herein we characterize novel in  vitro microfluidic 
model of the BTB and BBB (as a reference point) using a 
co-culture of human umbilical endothelial cells (one of a 
number of endothelial cell lines used in a number of BBB 
studies [25, 26]) and brain metastases cells. This model 
incorporates flow during culture of the endothelia and 
has a micro-tubular lumen, which in other work has sub-
stantially reduced limitations seen in transwells [27–31]. 
This model is unique from other flow based models in 
that it allows for a co-culture or triple culture of relevant 
cells, it is easily duplicated, it is commercially available 
and provides a cost-effective solution for running multi-
ple and parallel assays.
Methods
Microfluidic device
Co-culture idealized microvascular networks used in 
this study were obtained from SynVivo Inc. Huntsville, 
AL. The device consists of a central compartment (baso-
lateral) that is comprised of the brain tissue cells (astro-
cytes, pericytes, neurons) and the outer compartment 
(apical) that is comprised of the endothelial cells and pro-
vides perfusion similar to physiological fluid flow condi-
tions. The outer compartments and central compartment 
are separated by an interface with a series of 3 μm pores 
along the length, replacing the use of membranes in con-
ventional models.
Chemicals
Sulforhodamine 101 acid chloride (Free TRD), Rho-
damine 123 (Rho123), Texas Red 3000  MW Dextran 
(TRD 3 kDa), and Texas Red 70,000 MW Dextran (TRD 
70  kDa) were purchased from ThermoFisher Scientific 
(Grand Island, NY). Verapamil was purchased from 
Sigma (St. Louis, MO). Cyclosporine A was purchased 
from Toronto Research Chemicals Inc. (Toronto, Can-
ada). All other chemicals used were of analytical grade 
and were used as supplied.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were 
purchased from Lonza (Allendale, NJ). CTX-TNA2 rat 
brain astrocytes were kindly donated by Dr. Jim Simpkins 
(West Virginia University, Morgantown, WV). Met-1 
murine metastatic breast cancer cells were a kind gift 
from Dr. Alexander Borowsky (UC Davis, Sacramento, 
CA). All cells were maintained in endothelial basal 
medium-2 (EBM-2) supplemented with the EGM-2 Bul-
letKit from Lonza (Allendale, NJ). Cells were grown in 
a 37  °C humidified incubator with 5% CO2 until  ~85% 
confluent.
Cell culture in microfluidic chip
Matrigel (40  μg  cm−2, EMD Milipore, Billerica MA) 
was injected into the central compartment and allowed 
to sit covered in ice for approximately 1  h, after which 
serum-free media was promptly injected to wash the 
central compartment. Fibronectin (200  μg  mL−1, EMD 
Milipore, Billerica MA) was then injected into one of 
the outer sides of the device and allowed to incubate 
at 37  °C overnight. Prior to the seeding of all cells, the 
device was flushed with EBM-2 media. Astrocytes/Met-1 
cells were harvested using TrypLE Select (ThermoFisher, 
Waltham MA) and re-suspended into a final concen-
tration of  ~1  ×  107  mL−1 cells for injection, and were 
seeded at a flow rate of 10 μL min−1 in the central com-
partment using a Pump 11 Elite Nanomite programmable 
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syringe pump (Harvard Apparatus, Holliston MA). The 
inlet port tubing was clamped when cells reached a 
central compartment density of  ~50%, and chip was 
transferred to a CO2 incubator at 37 °C to allow cells to 
attach for 2  h. HUVECs were harvested using TrypLE 
Select (ThermoFisher, Waltham MA) in the same pro-
cess described above, re-suspended to a concentration 
of  ~1 ×  107  mL−1,  and seeded into the outer compart-
ment previously coated with Fibronectin at a flow rate of 
6  μL  min−1 using a Pump 11 Elite Nanomite program-
mable syringe pump (Harvard Apparatus, Holliston MA). 
Inlet port tubing was clamped when HUVECs reached an 
intra-outer compartment density of ~90%, then chip was 
transferred to a CO2 incubator at 37  °C and cells were 
allowed to attach for 24  h, with the exception of media 
refreshment. After 6 h of incubation, medium in central 
and both outer compartments was replaced with fresh 
EBM-2 medium. Media replacement was repeated again 
at 24  h. Astrocyte/Met-1 cells were maintained in the 
central compartment under static conditions in EBM-2 
medium while EBM-2 medium was prepared in syringes 
mounted on a programmable PHD 2000 syringe pump 
(Harvard Apparatus, Holliston MA) and then connected 
to the chips through ~12 in. of sterile Tygon tubing (Har-
vard Apparatus, Holliston MA). This medium was flowed 
at a flow rate of 0.02 μL min−1 over the seeded HUVECs 
in the outer compartment for 4  h, then increased to 
0.05 μL min−1 after 4 h, and finally to 0.1 μL min−1 after 
4 more hours, equivalent to 1.9 × 10−3 dynes cm−2 [32] 
This flow rate of 0.1  μL  min−1 was then maintained for 
24 h.
In vitro transport studies
EBM-2 Medium was incubated in a BD Luer-Lok 
Syringe with either Free TRD (600  mg  mL−1), TRD 
3  kDa (600  mg  mL−1), TRD 70  kDa (600  mg  mL−1), or 
with R123 (600 mg mL−1) in the presence or absence of 
known P-gp inhibitors (verapamil: 50 mM, Cyclosporine 
A: 10 mM) and mounted on a programmable PHD 2000 
syringe pump (Harvard Apparatus, Holliston MA), with 
syringes connected to chips through sterile Tygon tub-
ing (Harvard Apparatus, Holliston MA). Permeability 
was measured through the injection of desired tracer 
into the outer compartment at 0.1  μL  min−1 for a total 
of 90 min while brightfield images (acquired at a 25 ms 
exposure) and fluorescent images (acquired at a 200 ms 
exposure) were acquired every 2  min. Permeability of 
each tracer was determined using NIS Elements Imaging 
Software. Using linear regression (Prism 6.0), the slope 
of the best-fit line was used to represent the relative kin, 
or rate of accumulation, of fluorescence in the central 
compartment (comparable to the concentration of drug 
found in normal brain) divided by the accumulation of 
fluorescence in the outer compartment (comparable to 
the concentration of drug found in the plasma of the BBB 
vasculature). Unless otherwise stated, data are presented 
as mean ± SEM.
Quantification of fluorescent tracers using fluorescent 
microscopy
Chips were mounted on an automated stage enclosure, 
maintained at 37  °C with 5% CO2, on a Nikon Eclipse 
TE2000-E Live Cell Sweptfield Confocal microscope 
(Melville, NY). Acquisition of images and fluorescence 
was achieved through the utilization of a Photometrics 
CoolSnap HQ2 Monochrome CCD Camera (Tucson, 
AZ) with a 20×/0.75 Plan Fluor Phase Contrast objec-
tive with a total field of 6  ×  8, stitching images using 
brightfield with a 10% overlay. Brightfield and fluores-
cent images were taken every 2 min for 90 min. Excita-
tion and emission of Free Texas Red, Texas Red 3 and 
70  kDa, was obtained using the TRITC epiflourescence 
filter (peak fluorophore excitation is 596  nm and emis-
sion is 615 nm); excitation filter wheel of 555/25×, emis-
sion filter wheel of 605/52 m and dichromatic mirror at 
89,000 sedat quad. The excitation and emission of Rhoda-
mine 123 (±Cyclosporine A or Verapamil) was obtained 
using the FITC epiflourescence filter (peak fluorophore 
excitation is 511 nm and emission is 534 nm); excitation 
filter wheel of 490/20×, emission filter wheel of 525/36 m 
and dichromatic mirror at 89,000 sedat quad.
Kinetic analysis
Unidirectional uptake transfer constants (kin) were calcu-
lated from the following relationship to the linear portion 
of the uptake curve:
where CCC is the sum intensity of fluorophore in the 
region of interest in the central compartment (au) at the 
end of perfusion, CPF is the sum intensity of fluorophore 
(au) in the region of interest within the outer compart-
ment, t is the perfusion time in minutes, and OC is the 
extrapolated intercept [T =  0  min; “outer compartment 
volume” (au)]. After the determination of a perfusion 
time where an adequate amount of fluorescent marker 
was allowed to pass into brain, while still remaining in 
the linear uptake zone, kin was determined [33].
Statistical analysis
The slope of the line (kin) was determined with linear 
regression using best-fit values. One-way ANOVA analy-
sis and unpaired t test with Welch’s correction, followed 
by an F test to compare variances were used for the com-
parison of the kin values between unrestricted diffusion, 
BBB, and BTB among each tracer and with Rho123 in 
(1)(CCC + CPF) / CPF = kin(t) + OC
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absence and presence of inhibitors. For all data, errors 
are reported as standard error of the mean unless other-
wise indicated. Differences were considered statistically 
significant at the p < 0.05 levels (GraphPad Prism version 
6.00 for Mac, GraphPad Software, San Diego, CA, USA).
Results
In this study, we evaluate transfer rates of Free TRD, 
Texas Red 3  kDa, Texas Red 70  kDa, and Rho123 (with 
and without inhibitors) (Fig.  1) in a novel microfluidic 
BBB and BTB model as validation to previously pub-
lished literature [34]. Briefly in this model, endothelial 
cells are seeded in the outer compartments, while astro-
cytes (BBB) or brain seeding breast cancer cells (BTB) are 
seeded in the central compartment. The porous architec-
ture between the two compartments allows for cellular 
crosstalk and biochemical exchanges, while shear stress 
from perfusate flow facilitates development of endothe-
lial morphology [19]. Confocal brightfield images show 
the differences in morphology between endothelial cells 
with and without flow (Fig.  1b, c). In order to verify a 
confluent 360° coating of endothelial cells within the 
outer compartment, we used a Nikon A1R Confocal on 
Eclipse TiE Microscope to acquire a 3D z-stack of the 
outer compartment. Utilizing this system, DAPI stained 
endothelial cells were imaged from the bottom (Fig. 2a), 
through to the top (Fig.  2b) showing HUVECs wrap-
ping around the sides of the outer compartment (Fig. 2c) 
connecting the HUVECs on the top to the HUVECs on 
the bottom, verifying confluent formation of a tubular 
in vitro microvasculature.
In initial kinetic experiments, we determined unre-
stricted diffusion rates of difference sized molecules by 
perfusing solutes through microfluidic chips without 
endothelial cells or astrocytes/cancer cells. To quantify 
tracer accumulation, regions of interest were selected to 
determine sum fluorescence intensity in the outer com-
partment (ROI 136), central compartment (ROI 139), 
and background (ROI 165) over time (1D). ROI 165 
was taken to ensure data received in the outer and cen-
tral compartments were significant when compared to 
the background sum fluorescence. We observed (Fig.  3) 
that small tracers (<1000  Da) had a diffusion rate of 
22.8 ± 2.5 × 10−3, n = 6, which was not significantly dif-
ferent compared to tracers of molecular weights between 
3 and 5  kDa (22.1  ±  8.5  ×  10−3, n  =  3) and  >60  kDa 
(17.5 ± 4.2 × 10−3, n = 3).
In our next experiments, we qualitatively imaged 
Texas Red accumulation from 0 to 90  min in the BBB 
model (Fig.  4a–d). Linear accumulation of the dye in 
the central chamber of the BBB model is quantitatively 
shown in Fig. 4e. We then determined kin values for each 
tracer in both the BBB and BTB model, given in units 
of (µL  min−1) according to the equation found in our 
methods. Free Texas Red kin values (Fig. 5a) for the BBB 
(2.5 ± 0.3 × 10−3, n = 6) and BTB (13.1 ± 1.3 × 10−3, 
n  =  4) were significantly different (p  <  0.05) between 
each other. Texas Red 3 kDa values (Fig. 5b) for the BBB 
(0.1 ±  0.1 ×  10−3, n =  3) and BTB (1.8 ±  1.0 ×  10−3, 
n = 3) and Texas Red 70 kDa values (Fig. 5c) for the BBB 
(1.1 ±  0.9 ×  10−3, n =  3) and BTB (4.5 ±  2.4 ×  10−3, 
n =  3) were also significant (p  <  0.05) when compared 
to the unrestricted diffusion kin, but significance was 
not observed between the BBB and BTB models of these 
dyes.
To determine if P-gp inhibitors alter the accumula-
tion of P-gp sensitive fluorescent dye accumulation into 
the central compartment we perfused Rho123 in the 
absence and presence of P-gp inhibitors Cyclosporine 
A (10  mM), and Verapamil (50  mM)—concentrations 
that ensured maximal inhibition [34]. We qualitatively 
observed an increase in dye accumulation in the cen-
tral compartment over the course of 90 min in both the 
BBB (Fig. 6a) and BTB (Fig. 6b) models (Fig. 6c). Quan-
titatively, we observed a 14-fold increase of Rho123 
in the central compartment, in the presence of P-gp 
inhibitor Verapamil (14.7  ±  7.5  ×  10−3, n  =  3), and a 
significant (p < 0.05) eight fold increase of Rho123 with 
Cyclosporine A (8.8  ±  1.8  ×  10−3, n  =  3) when com-
pared to control Rho123 (0.6  ±  0.1  ×  10−3, n  =  4) in 
the BBB model (Fig.  6d). Similarly in the BTB model, a 
threefold increase was observed in Rhodamine 123 per-
meability in the presence of P-gp inhibitor Verapamil 
(10.3 ± 3.1 × 10−3, n = 3), and a twofold increase with 
Cyclosporine A (7.1 ± 5.2 × 10−3, n = 3) when compared 
to Rho123 control (3.2 ± 2.8 × 10−3, n = 3) (Fig. 6e).
Discussion
The results of the studies presented herein suggest that 
a novel microfluidic chip in part mimics the in  vivo 
BTB with regard to passive permeability and efflux [16]. 
Importantly, this study demonstrates that perfusion flow 
through the luminal compartment improves endothe-
lial function. This model also has potential to be used in 
screening assays for drug discovery and development for 
central nervous system disease.
Predominant in vitro BBB models have some key simi-
larities. First, there is a presence of some type of “barrier” 
cell in a luminal or outer compartment (representing 
the vascular lumen). These cells range from primary or 
immortalized brain endothelial cells (most commonly rat, 
mouse, or human), peripheral endothelial (HUVECs), or 
stem-cell derived cells. In this study HUVECs were cho-
sen as they are commonly used by a number of labs, and 
using a co-culture of astrocytes or even astrocyte-condi-
tioned media alone has been shown to induce BBB-like 
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Fig. 1 a Schematic of SynVivo BBB microfluidic chip: (1) inlet port where media with or without tracer is flowed through the outer compartment to 
change media for HUVECs. (2) Outer compartment, containing HUVECs. (3) 3 μm pores, to allow diffusion of media and tracer between the central 
and outer compartments. (4) Central compartment, containing astrocytes or cancer cells. (5) Outlet port where perfusate from the outer compart‑
ment is collected. (6) Inlet port for central compartment, used to seed and change media for the astrocytes/cancer cells in the central compart‑
ment. (7) Output ports where perfusate from the central compartment is collected. b Morphology of astrocytes in the central compartment and 
HUVECs in the outer compartment without the addition of flow (c) morphology of astrocytes in the central compartment and HUVECs in the outer 
compartment with the addition of flow. d Representation of where the regions of interest (ROI) measurements are taken for data analysis. White 
rectangle scale bars 500 μm
Fig. 2 3‑dimensional confocal images of DAPI labeled HUVECs in the outer compartment demonstrating a 360o coating of cells. The nuclei of the 
HUVECs are seen on the bottom (a) and top (b) and in a side view (c)
Page 6 of 10Terrell‑Hall et al. Fluids Barriers CNS  (2017) 14:3 
expression of tight junctions and barrier tightness in 
a variety of endothelial cells [20, 29, 35]. These barrier 
cells typically express tight junction proteins, which seal 
the endothelial cells together and produce higher TEER 
values [36]. Second, the models usually include the pres-
ence of a semipermeable basement membrane separating 
the outer (lumen) and central (brain side) compartments. 
Lastly, cells, typically astrocytes and or pericytes, are 
seeded in the central compartment in an effort to mimic 








































Fig. 3 The diffusion rates of free MW tracers <1000 Da, 3–5 kDa 
and >60 kDa in an unrestricted, cell free microfluidic chips are shown. 
Statistical significance was determined using one‑way ANOVA 
followed by Tukey’s multiple comparison tests, and student’s t test; 





















Fig. 4 Representative timelapse images showing passive diffusion 
of Free TRD from the outer to the central compartment. Intensity of 
fluorescence increases linearly over time 0 min (a), 30 min (b), 60 min 
(c), and 90 min (d). e Linear concentration of tracer movement versus 












































































Fig. 5 Linear central compartment accumulation of Free Texas Red 
(a), Texas Red 3 kDa (b), and Texas Red 70 kDa (c) in BBB and BTB 
SynVivo chip models. Images show rate of each tracer within each 
model. Statistical significance was determined using one‑way ANOVA 
followed by Tukey’s multiple comparison tests, and student’s t test; 
*p < 0.05 significance between tracer and unrestricted diffusion 
kin, n = 3–6; +p < 0.05 significance between BBB and BTB models, 
n = 3–6. All data represent mean ± SEM
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provide cell to cell communication to the endothelial 
cells in the outer compartment, resulting in the forma-
tion of tighter barrier and an increase in TEER [4, 17, 37]. 
Germane to this work, to re-create the BTB, astrocytes 
and or pericytes are replaced with tumor cells in the 
central compartment. In  vivo, angiogenesis occurs with 
the establishment of tumor tissue, resulting in the pres-
ence of fenestrations, gaps between the endothelial cells, 
varied expression of efflux transporters, and an increase 



































































































Fig. 6 Representative brightfield image of Rhodamine 123 dye accumulation in the central compartment after 90 min of perfusion in the BBB 
model without an inhibitor (a) and with an inhibitor (b). Rate of fluorescent dye accumulation of Rho123 into central compartment after 90 min of 
dye perfusion in BBB, and BTB chips (c). Rate of fluorescent dye accumulation in BBB (d) and BTB (e) chips perfused with Rho123 ± P‑gp inhibitors 
(Cyclosporine A or Verapamil). Statistical significance was determined using one‑way ANOVA followed by Tukey’s multiple comparison tests, and 
student’s t test; *p < 0.05 significance between tracer and unrestricted diffusion kin, n = 3–4; +p < 0.05 significance between BBB/BTB models and 
the addition of inhibitor, n = 3–6. All data represent mean ± SEM. White rectangle scale bars 500 μm
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The use of dyes has been a long-standing method to 
evaluate the integrity of the BBB and the breakdown of 
the BTB [39]. Some of the earliest work using dyes dates 
back to the nineteenth century, where Paul Ehrlich and 
Edwin Goldmann intravenously injected water-soluble 
dyes and observed that dyes did not have the ability to 
freely exchange between the vascular and brain paren-
chyma compartment (reviewed in [34]). Dyes have also 
been used as a tool to visualize and qualitatively measure 
disruption at the BBB [40–44] as well as the BTB [16, 34]. 
Passive permeability dyes are a simple way to compare 
rates of diffusion between different models in  vivo and 
in vitro.
In measuring the unrestricted diffusion (the absence of 
cells) of molecules from the outer chamber to the center 
chamber, we observed that the diffusion rates (kin), from 
the outer compartment to the central compartment, of 
all three sized molecules were not significantly different 
from each other. This data is consistent with previous 
work showing that if the diameter of each molecule being 
tested is at least 12×  less than the barrier defects, then 
diffusion will remain constant for all molecules [45].
An interesting aspect of our observations was the 
similarity of efflux function that existed in the microflu-
idic model compared to the in vivo BBB [9]. Rhodamine 
123 is subject to P-gp mediated efflux at both the BBB 
and the BTB. When rhodamine 123 and an inhibitor of 
P-gp are administered concurrently, dye accumulates in 
brain ~10- to 12-fold higher than in the absence of efflux 
inhibition [34]. Similarly, in this work, when Verapamil 
or Cyclosporine A was added to the outer chamber of 
the microfluidic device, Rhodamine 123 accumulation 
increased similar to in  vivo reports [9]. Further, P-gp 
function retains function despite barrier breakdown in a 
number of pathologies [9, 46]. The data herein agree that 
the degree of efflux function for the BTB, though dis-
rupted, is intact and it retains the ability to restrict drug 
and dye movement from the vasculature to the brain 
compartment.
Transwells are a widely used in vitro method to study 
the BBB. Transwells are cheap, available in high through-
put assays, and easy to use. However, there are substan-
tial limitations. First, transport kinetics in transwell 
systems are strongly influenced by an unstirred water 
layer that exists on the outer side of the endothelial cells. 
The unstirred water layer may decrease the apparent per-
meability rate of lipid soluble and increase to some extent 
water-soluble molecules. Second, because the cells are 
grown in a static media, there is no shear stress (or flow) 
forced on the endothelial cells, which may contribute to 
the low passive permeability measurements which can 
be as low as ~74 Ω cm2 [47], compared to in vivo values 
of ~2000 Ω cm2 [48]. While a few other in vitro models 
and microfluidic devices have a flow component [27–31], 
this microfluidic device is the first commercially available 
blood-tumor barrier using a microfluidic model seeded 
with brain-seeking cells and with shear stress similar to 
that observed in vivo [19] in addition to real-time visuali-
zation and quantitation.
Conclusions
This novel and dynamic microfluidic in  vitro BTB 
model mimics the in vivo barrier with regard to shear 
stress, permeability, and efflux. Permeability of large 
molecule dextrans, as well as small molecule dextrans 
and Rhodamine 123 (with and without inhibitors) were 
characteristic and relatable to what is seen in vivo. The 
shear stress from adding flow over HUVECs eliminates 
the unstirred water layer and allows for different trac-
ers to be added and followed in real time from outer 
to central compartment. Based on these characteristics, 
this microfluidic chip shows potential for use in BBB 
and BTB research. Expanding on these data, future 
work should entail the use of different drugs, and the 
comparison of different endothelial cell models to 
in  vivo data with regards to passive permeability and 
influx/efflux.
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